Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Abemaciclib

FDA-approved product (tablet, oral), marketed as Verzenio.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Abemaciclib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • HER2 Positive Breast Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Cyclin-dependent kinase (cdk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Abemaciclib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Abemaciclib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

    NCT06062498 · start 2023-09-29

    Registered record
    Registry ID
    NCT06062498
    Conditions
    Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer
    Interventions
    elacestrant, palbociclib, abemaciclib, ribociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-09-29
    Completion
    2029-07-01
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer
    Interventionelacestrant, palbociclib, abemaciclib, ribociclib
    PhasePhase 2
    Registry statusRecruiting

  • Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

    NCT06152471 · start 2023-06-07

    Registered record
    Registry ID
    NCT06152471
    Conditions
    Early-stage Breast Cancer; Diarrhea; Adverse Drug Event
    Interventions
    SPC-flakes; Salovum; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-06-07
    Completion
    2025-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly-stage Breast Cancer; Diarrhea; Adverse Drug Event
    InterventionSPC-flakes; Salovum; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

    NCT06344780 · start 2023-05-20

    Registered record
    Registry ID
    NCT06344780
    Conditions
    Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-05-20
    Completion
    2025-02-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Implantable Microdevice for TNBC - Pilot Study

    NCT05774886 · start 2023-05

    Registered record
    Registry ID
    NCT05774886
    Conditions
    Triple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer; Early Stage Triple-Negative Breast Carcinoma; Breast Neoplasms; Breast Carcinoma
    Interventions
    Implantable Microdevice (IMD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-05
    Completion
    2028-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer +3 more
    InterventionImplantable Microdevice (IMD)
    PhasePhase 1
    Registry statusWithdrawn

  • Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    NCT05735080 · start 2023-03-28

    Registered record
    Registry ID
    NCT05735080
    Conditions
    Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Ovarian Cancer; CCNE1 Amplification; Solid Tumor; Advanced Cancer; Metastatic Cancer
    Interventions
    INX-315; Fulvestrant; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-03-28
    Completion
    2027-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast +5 more
    InterventionINX-315; Fulvestrant; Abemaciclib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

    NCT05548127 · start 2023-02-23

    Registered record
    Registry ID
    NCT05548127
    Conditions
    Breast Cancer
    Interventions
    ARV-471; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2023-02-23
    Completion
    2027-03-24
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionARV-471; Abemaciclib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

    NCT05714072 · start 2023-01-25

    Registered record
    Registry ID
    NCT05714072
    Conditions
    Myelofibrosis Due to and Following Polycythemia Vera
    Interventions
    Ruxolitinib; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-01-25
    Completion
    2027-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelofibrosis Due to and Following Polycythemia Vera
    InterventionRuxolitinib; Abemaciclib
    PhasePhase 1
    Registry statusRecruiting

  • Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

    NCT05386108 · start 2022-08-31

    Registered record
    Registry ID
    NCT05386108
    Conditions
    Breast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Central Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases
    Interventions
    Elacestrant; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2022-08-31
    Completion
    2026-12
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Brain Neoplasms; Neoplasms by Site; Neoplasms +4 more
    InterventionElacestrant; Abemaciclib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

    NCT05524584 · start 2022-08-31

    Registered record
    Registry ID
    NCT05524584
    Conditions
    Breast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
    Interventions
    Fulvestrant; Anastrozole; Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-08-31
    Completion
    2031-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Metastatic Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer
    InterventionFulvestrant; Anastrozole; Abemaciclib
    PhasePhase 2
    Registry statusRecruiting

  • Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

    NCT05789771 · start 2022-04-01

    Registered record
    Registry ID
    NCT05789771
    Conditions
    HR+/HER2- Breast Cancer; Metastatic Disease; Аdvanced Disease
    Interventions
    Abemaciclib; Abemaciclib; Abemaciclib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-04-01
    Completion
    2022-12-01
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHR+/HER2- Breast Cancer; Metastatic Disease; Аdvanced Disease
    InterventionAbemaciclib; Abemaciclib; Abemaciclib
    PhaseNot recorded
    Registry statusCompleted

  • A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

    NCT05189717 · start 2022-02-17

    Registered record
    Registry ID
    NCT05189717
    Conditions
    Metastatic or Local Advanced Breast Cancer of Patients
    Interventions
    HRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-02-17
    Completion
    2025-07-31
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic or Local Advanced Breast Cancer of Patients
    InterventionHRS-8080 tablets、SHR 6390 tablets、Abemaciclib、Everolimus
    PhasePhase 1
    Registry statusUnknown

  • Abemaciclib With or Without Atezolizumab for mCRPC

    NCT04751929 · start 2021-08-20

    Registered record
    Registry ID
    NCT04751929
    Conditions
    Prostate Cancer; Metastatic Castration-resistant Prostate Cancer
    Interventions
    Abemaciclib; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-08-20
    Completion
    2025-11-06
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Metastatic Castration-resistant Prostate Cancer
    InterventionAbemaciclib; Atezolizumab
    PhasePhase 2
    Registry statusCompleted

  • Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)

    NCT04169074 · start 2021-07-07

    Registered record
    Registry ID
    NCT04169074
    Conditions
    HNSCC
    Interventions
    Abemaciclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-07-07
    Completion
    2025-01-13
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHNSCC
    InterventionAbemaciclib
    PhasePhase 2
    Registry statusTerminated

  • PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

    NCT04584853 · start 2020-12-23

    Registered record
    Registry ID
    NCT04584853
    Conditions
    Breast Cancer Female
    Interventions
    Abemaciclib; Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-12-23
    Completion
    2030-10
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female
    InterventionAbemaciclib; Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
    PhasePhase 3
    Registry statusActive not recruiting

  • LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

    NCT04616183 · start 2020-12-02

    Registered record
    Registry ID
    NCT04616183
    Conditions
    Metastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma; Stage III Colon Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8; Stage IV Colon Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Rectal Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Rectal Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Rectal Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage IVC Rectal Cancer AJCC v8; Unresectable Colon Adenocarcinoma; Unresectabl
    Interventions
    Abemaciclib; Cetuximab; ERK1/2 Inhibitor LY3214996
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-12-02
    Completion
    2028-12-31
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colon Adenocarcinoma; Metastatic Colorectal Carcinoma; Metastatic Rectal Adenocarcinoma; Recurrent Colorectal Carcinoma +26 more
    InterventionAbemaciclib; Cetuximab; ERK1/2 Inhibitor LY3214996
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting